^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PYX-106

    i
    Other names: PYX-106, BSI-060T, BSI 060T, PYX 106, BSI060T, PYX106
    Associations

    News

    Trials
    Company:
    Biosion, Pyxis Oncology
    Drug class:
    SIGLEC15 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    Study of PYX-106 in Solid Tumors (clinicaltrials.gov)
    P1, N=47, Active, not recruiting, Pyxis Oncology, Inc | Trial completion date: Aug 2025 --> May 2026 | Trial primary completion date: Aug 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    PYX-106
    1year
    Study of PYX-106 in Solid Tumors (clinicaltrials.gov)
    P1, N=47, Active, not recruiting, Pyxis Oncology, Inc | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    PYX-106
    over1year
    Associations of the immunomodulatory molecule Siglec-15 gene and protein expression to immune gene signatures as a potential biomarker for Siglec-15 targeted therapy in non-small cell lung cancer (SITC 2024)
    Siglec-15 is a novel immunosuppressive protein expressed on tumor associated macrophages (TAMs) and tumor cells in many indications and is currently under clinical investigation (PYX-106, NCT05718557)...The co-expression of Siglec-15 and PD-L1 in tumors may inform indication selection for combination therapies. Future studies will expand this data set for NSCLC and evaluate other indications.
    PD(L)-1 Biomarker • Gene Signature • IO biomarker • Immunomodulating
    |
    SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
    |
    SIGLEC15 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    PYX-106
    over1year
    Study of PYX-106 in Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Pyxis Oncology, Inc | N=45 --> 60 | Trial primary completion date: Apr 2024 --> Dec 2024
    Enrollment change • Trial primary completion date • Metastases
    |
    PYX-106
    over2years
    First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors (SITC 2023)
    1 criteria and safety findings are reviewed by the dose escalation steering committee, which monitors the safety and recommends dose(s) for Part 2. The study population includes participants with histologically or cytologically confirmed solid tumors including non-small cell lung cancer (without driver mutations/translocations), breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.
    Clinical • P1 data • PK/PD data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
    |
    PD-L1 expression • SIGLEC15 expression
    |
    PYX-106
    almost4years
    BSI-060T, a high affinity, fully human anti-siglec-15 antibody as an alternative immune checkpoint blocker (AACR 2022)
    BSI-060T exhibits best-in-class biophysical properties and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies.
    Checkpoint inhibition • IO Companion diagnostic • PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
    |
    SIGLEC15 expression
    |
    PYX-106